Investors & Media
Press Releases
2024
-
- December 19, 2024
-
Anokion Announces the Early Completion of Enrollment in the ACeD-it Phase 2 and the SynCeD Phase 2a Trials of KAN-101 for the Treatment of Celiac Disease
Read More
-
- September 18, 2024
-
Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis
Read More
-
- May 20, 2024
-
Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
Read More